Close Menu

NEW YORK (GenomeWeb) – Quanterix today announced it has won a Phase II Head Health Challenge I grant from GE and the National Football League to address the diagnosis and prognosis of brain trauma.

Quanterix will receive $500,000 to develop tests that will attempt to quickly diagnose traumatic brain injuries almost immediately after they occur. The firm will also develop a point-of-care testing device to run multiplex panels of the biomarkers. Quanterix was one of six winners chosen from 16 finalists in the challenge.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.